8 completed, 1 terminated. 9 Phase 2.
By phase and status
Follow GS-9451: new trials by email Literature Review of GS-9451 trials Research Report on GS-9451
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis LDV/SOF, VDV, RBV - Hepatitis C Virus Infection Phase 2 Completed 47 2014-07-01 2018-11-16 Combination Therapy for Chronic Hepatitis C Infection Sofosbuvir, Ledipasvir, GS-9669 - Hepatitis C, Chronic Phase 2 Completed 229 2013-01-01 2017-06-08 GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection GS-5885 tablet, GS-9451 tablet, tegobuvir capsule - Chronic Genotype 1a or 1b HCV Infection Phase 2 Completed 163 2011-09-01 2013-12-20 GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection GS-5885, GS-9451, tegobuvir - Hepatitis C, Chronic Phase 2 Completed 170 2011-09-01 2013-12-17 GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype GS-5885, GS-9451, RBV - Chronic Hepatitis C Phase 2 Terminated 248 2011-08-01 2014-02-03 Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a - Hepatitis C, Chronic Phase 2 Completed 163 2011-07-01 2014-02-11 GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus GS-5885, GS-9451, peginterferon alfa-2a - Hepatitis C, Chronic Phase 2 Completed 351 2011-07-01 2014-02-03 GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection GS-5885, Tegobuvir, GS-9451 - Hepatitis C, Chronic Phase 2 Completed 141 2011-05-01 2013-12-20 A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Tegobuvir (GS-9190), GS-9451, Pegasys® - Hepatitis C, Chronic Phase 2 Completed 245 2010-10-01 2014-02-06
Conditions studied Hepatitis C (7) · Hepatitis C, Chronic (7)
Sponsors Gilead Sciences (8) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Countries United States (9) · Puerto Rico (4) · Australia (2) · Canada (2) · Germany (2) · Austria (1) · Belgium (1) · France (1) · Netherlands (1) · New Zealand (1) · Poland (1) · United Kingdom (1)
Top investigators Bittoo Kanwar, MD (2) · John McNally, PhD (2) · Benedetta Massetto, MD, PhD (1) · Bittoo Kanwar (1) · Henry Masur, M.D. (1) · Robert Hyland, DPhil (1)
Results publications PMID 25364884 , PMID 25591505 , PMID 26187031 , PMID 26521268 , PMID 26595450 , PMID 26612014 , PMID 26691547